Bioanalytical services specialist Alderley Analytical has been acquired by Dutch firm Synexa Life Sciences.
Synexa is backed by major European healthcare investor Gilde Healthcare.
Alderley Analytical, founded in 2013 and operational since 2014, has grown significantly since securing initial investment from River Capital and has established itself as a key player in supporting drug development programmes through discovery, pre-clinical safety testing and clinical development.
The company now employs around 60 highly qualified staff and has over 200 clients. It recently relocated to specially designed laboratories at Tytherington Business Park near Macclesfield.
“Becoming a part of the Synexa Group is a fantastic next step for our business which will allow us to accelerate our growth plan,” said Paul Holme, co-founder and director.
“Both parties in this acquisition will bring a valued opportunity to each business.
“There is a strong strategic rationale in bringing Alderley Analytical and Synexa together with many commercial synergies already identified.”
The initial six-figure investment was made in July 2015 through the North West Biomedical Fund, which was initially managed by SPARK Impact and which has since operationally merged with River Capital. The fund expects to receive more than four times its initial funding.
Jerry Mobbs, portfolio director at River Capital, commented on the exit: “Our investment in Alderley Analytical exemplifies River Capital’s commitment to supporting innovative businesses in the North West.
“The company’s growth from a startup to a major player in the bioanalytical services sector is a testament to the hard work of its founders and the potential of the region’s biomedical industry.”